Cationic lipid-polymer hybrid nanoparticle drives in situ generation and lymphatic navigation of tumor antigens to prime systemic antitumor immunity
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Nanoplatforms for cancer theranostics · Cancer Immunotherapy and Biomarkers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (42)
Show source-provided references
1. Vaccine development for emerging infectious diseases10.1038/s41591-021-01301-0 ↗
2. Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health10.1038/s41565-020-0739-9 ↗
3. Therapeutic cancer vaccines10.1038/s41568-021-00346-0 ↗
4. Cancer vaccines: Building a bridge over troubled waters10.1016/j.cell.2022.06.035 ↗
5. Cancer vaccines: the next immunotherapy frontier10.1038/s43018-022-00418-6 ↗
6. Identification of neoantigens for individualized therapeutic cancer vaccines10.1038/s41573-021-00387-y ↗
7. Turning the corner on therapeutic cancer vaccines10.1038/s41541-019-0103-y ↗
8. Elements of cancer immunity and the cancer–immune set point10.1038/nature21349 ↗
9. Oncology meets immunology: the cancer-immunity cycle10.1016/j.immuni.2013.07.012 ↗
10. Personalized vaccines for cancer immunotherapy10.1126/science.aar7112 ↗
11. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads10.1073/pnas.2102611118 ↗
12. Immunological mechanisms responsible for radiation-induced abscopal effect10.1016/j.it.2018.06.001 ↗
13. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance10.1016/j.immuni.2013.06.014 ↗
14. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors10.1038/s41571-020-0413-z ↗
15. Immunogenic cell stress and death10.1038/s41590-022-01132-2 ↗
16. Systemic immune responses to irradiated tumours via the transport of antigens to the tumour periphery by injected flagellate bacteria10.1038/s41551-021-00834-6 ↗
17. In situ cancer vaccination using lipidoid nanoparticles10.1126/sciadv.abf1244 ↗
18. Development of an in situ cancer vaccine via combinational radiation and bacterial-membrane-coated nanoparticles10.1002/adma.201902626 ↗
19. Supramolecular assembled programmable nanomedicine as in situ cancer vaccine for cancer immunotherapy10.1002/adma.202007293 ↗
20. A tumor-to-lymph procedure navigated versatile gel system for combinatorial therapy against tumor recurrence and metastasis10.1126/sciadv.abb3116 ↗
21. Detection of immunogenic cell death and its relevance for cancer therapy10.1038/s41419-020-03221-2 ↗
22. Identification of a specific role for the Na, K-ATPase α2 isoform as a regulator of calcium in the heart
23. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death10.1126/scitranslmed.3003807 ↗
24. Identification and characterization of cardiac glycosides as senolytic compounds10.1038/s41467-019-12888-x ↗
25. Cationic nanocarriers induce cell necrosis through impairment of Na+/K+-ATPase and cause subsequent inflammatory response10.1038/cr.2015.9 ↗
26. Endoplasmic reticulum stress signals in the tumour and its microenvironment10.1038/s41568-020-00312-2 ↗
27. Ultrasound-augmented mitochondrial calcium ion overload by calcium nanomodulator to induce immunogenic cell death10.1021/acs.nanolett.0c04778 ↗
28. Metallo-alginate hydrogel can potentiate microwave tumor ablation for synergistic cancer treatment10.1126/sciadv.abo5285 ↗
29. Immunogenic cell death in cancer and infectious disease10.1038/nri.2016.107 ↗
30. Novel therapeutic applications of cardiac glycoside.10.1038/nrd2682 ↗
31. A magnetically driven amoeba-like nanorobot for whole-process active drug transport10.1002/advs.202204793 ↗
32. Magnetically actuated active deep tumor penetration of deformable large nanocarriers for enhanced cancer therapy10.1002/adfm.202103655 ↗
33. Engineering nanoparticulate vaccines for enhancing antigen cross-presentation10.1016/j.copbio.2020.06.015 ↗
34. Cross-presentation by dendritic cells10.1038/nri3254 ↗
35. Material design for lymph node drug delivery10.1038/s41578-019-0110-7 ↗
36. Application of nano-delivery systems in lymph nodes for tumor immunotherap10.1007/s40820-023-01125-2 ↗
37. The future of immune checkpoint therapy10.1126/science.aaa8172 ↗
38. Clinical challenges of immune checkpoint inhibitors10.1016/j.ccell.2020.07.004 ↗
39. The next decade of immune checkpoint therapy10.1158/2159-8290.CD-20-1680 ↗
40. Therapeutic cancer vaccines revamping: technology advancements and pitfalls10.1016/j.annonc.2021.08.2153 ↗
41. Toward understanding and exploiting tumor heterogeneity10.1038/nm.3915 ↗
42. Oncolysis without viruses—inducing systemic anticancer immune responses with local therapies10.1038/s41571-019-0272-7 ↗